Displaying all 9 drugs
Erlotinib
Erlotinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that is used in the treatment of non-small cell lung cancer, pancreatic cancer and several other types of cancer. It is typically marketed under the trade name Tarceva. Erlotinib binds to the epidermal growth factor receptor (EGFR)...
Approved
Investigational
Matched Synonyms: … [6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine …
Matched Iupac: … N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine …
Matched Description: … in the treatment of non-small cell lung cancer, pancreatic cancer and several other types of cancer. ... This finding introduces the potential use of erlotinib in the treatment of JAK2V617F-positive PV and ... form of tyrosine kinase JAK2 found in most patients with polycythemia vera (PV) and a substantial proportion …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Matched Iupac: … N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine …
Matched Description: … in the treatment of non-small cell lung cancer, pancreatic cancer and several other types of cancer. ... This finding introduces the potential use of erlotinib in the treatment of JAK2V617F-positive PV and ... form of tyrosine kinase JAK2 found in most patients with polycythemia vera (PV) and a substantial proportion …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Dacomitinib
Dacomitinib, designed as (2E)-N-16-4-(piperidin-1-yl) but-2-enamide, is an oral highly selective quinazalone part of the second-generation tyrosine kinase inhibitors which are characterized by the irreversible binding at the ATP domain of the epidermal growth factor receptor family kinase domains. Dacomitinib was developed by Pfizer Inc and approved by the FDA on...
Approved
Investigational
Matched Iupac: … (2E)-N-{4-[(3-chloro-4-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}-4-(piperidin-1-yl)but-2-enamide …
Matched Description: … [L4810] Some evidence in the literature suggests the therapeutic potential of dacomitinib in the epithelial ... [A40009] Dacomitinib was developed by Pfizer Inc and approved by the FDA on September 27, 2018. ... designed as (2E)-N-16-4-(piperidin-1-yl) but-2-enamide, is an oral highly selective quinazalone part of …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Matched Description: … [L4810] Some evidence in the literature suggests the therapeutic potential of dacomitinib in the epithelial ... [A40009] Dacomitinib was developed by Pfizer Inc and approved by the FDA on September 27, 2018. ... designed as (2E)-N-16-4-(piperidin-1-yl) but-2-enamide, is an oral highly selective quinazalone part of …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Remdesivir
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of coronavirus disease 2019 (COVID-19), which is a respiratory disease that is capable of progressing to viral pneumonia and acute respiratory distress syndrome (ARDS); COVID-19 can be fatal. Like other RNA viruses, SARS-CoV-2 depends on an RNA-dependent RNA polymerase...
Approved
Investigational
Matched Iupac: … 2-ethylbutyl (2S)-2-{[(S)-{[(2R,3S,4R,5R)-5-{4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl}-5-cyano-3,4-dihydroxyoxolan …
Matched Description: … 2 and the related SARS-CoV and MERS-CoV,[A222398] and has been investigated in multiple COVID-19 clinical ... [L18438] Remdesivir was also approved by the European Commission on July 3, 2020. ... 2019 (COVID-19), which is a respiratory disease that is capable of progressing to viral pneumonia and …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Nucleosides and Nucleotides ... Nucleic Acids, Nucleotides, and Nucleosides ... Nucleosides and Nucleotides Excl. Reverse Transcriptase Inhibitors …
Matched Description: … 2 and the related SARS-CoV and MERS-CoV,[A222398] and has been investigated in multiple COVID-19 clinical ... [L18438] Remdesivir was also approved by the European Commission on July 3, 2020. ... 2019 (COVID-19), which is a respiratory disease that is capable of progressing to viral pneumonia and …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Nucleosides and Nucleotides ... Nucleic Acids, Nucleotides, and Nucleosides ... Nucleosides and Nucleotides Excl. Reverse Transcriptase Inhibitors …
Risdiplam
Risdiplam is an orally bioavailable mRNA splicing modifier used for the treatment of spinal muscular atrophy (SMA). It increases systemic SMN protein concentrations by improving the efficiency of SMN2 gene transcription. This mechanism of action is similar to its predecessor nusinersen, the biggest difference being their route of administration: nusinersen...
Approved
Investigational
Matched Iupac: … 7-{4,7-diazaspiro[2.5]octan-7-yl}-2-{2,8-dimethylimidazo[1,2-b]pyridazin-6-yl}-4H-pyrido[1,2-a]pyrimidin …
Matched Description: … [L15351,A216871] Risdiplam was approved by the FDA in August 2020 for the treatment of spinal muscular ... [L12615] It increases systemic SMN protein concentrations by improving the efficiency of _SMN2_ gene ... route of administration: nusinersen requires intrathecal administration, as does the one-time gene therapy …
Matched Categories: … Survival of Motor Neuron 2 Splicing Modifier …
Matched Description: … [L15351,A216871] Risdiplam was approved by the FDA in August 2020 for the treatment of spinal muscular ... [L12615] It increases systemic SMN protein concentrations by improving the efficiency of _SMN2_ gene ... route of administration: nusinersen requires intrathecal administration, as does the one-time gene therapy …
Matched Categories: … Survival of Motor Neuron 2 Splicing Modifier …
Capmatinib
Capmatinib is a small molecule kinase inhibitor targeted against c-Met (a.k.a. hepatocyte growth factor receptor [HGFR]), a receptor tyrosine kinase that, in healthy humans, activates signaling cascades involved in organ regeneration and tissue repair. Aberrant c-Met activation - via mutations, amplification, and/or overexpression - is known to occur in many...
Approved
Investigational
Matched Iupac: … 2-fluoro-N-methyl-4-{7-[(quinolin-6-yl)methyl]imidazo[1,2-b][1,2,4]triazin-2-yl}benzamide …
Matched Description: … to occur in many types of cancer, and leads to overactivation of multiple downstream signaling pathways ... [L13347] Capmatinib was approved by Health Canada on June 8, 2022.[L42015] ... [A199122] Mutations in _MET_ have been detected in non-small cell lung cancer (NSCLC), and the prevalence …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Matched Description: … to occur in many types of cancer, and leads to overactivation of multiple downstream signaling pathways ... [L13347] Capmatinib was approved by Health Canada on June 8, 2022.[L42015] ... [A199122] Mutations in _MET_ have been detected in non-small cell lung cancer (NSCLC), and the prevalence …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Onasemnogene abeparvovec
Onasemnogene abeparvovec is an adeno-associated virus vector-based gene therapy that has been approved by the FDA in May 2019 for the treatment of infant patients (less than 2 years of age) with spinal muscular atrophy (SMA) and a specific mutation in the survival motor neuron 1 (SMN1) gene. SMA is...
Approved
Matched Description: … atrophy (SMA) and a specific mutation in the survival motor neuron 1 (SMN1) gene. ... [Nusinersen] is another gene therapy that is currently approved by the FDA for the treatment of SMA in ... The use and effectiveness of onasemnogene abeparvovec in patients with advanced SMA, such as those with …
Matched Categories: … Cellular and Gene Therapy ... Amino Acids, Peptides, and Proteins …
Matched Categories: … Cellular and Gene Therapy ... Amino Acids, Peptides, and Proteins …
Nusinersen
An antisense oligonucleotide that induces survival motor neuron (SMN) protein expression, it was approved by the U.S. FDA in December, 2016 as Spinraza for the treatment of children and adults with spinal muscular atrophy (SMA). It is adminstrated as direct intrathecal injection.
Approved
Investigational
Matched Description: … FDA in December, 2016 as Spinraza for the treatment of children and adults with spinal muscular atrophy …
Matched Categories: … Nucleic Acids, Nucleotides, and Nucleosides …
Matched Categories: … Nucleic Acids, Nucleotides, and Nucleosides …
Afatinib
Afatinib is a 4-anilinoquinazoline tyrosine kinase inhibitor in the form of a dimaleate salt available as Boehringer Ingelheim's brand name Gilotrif [FDA Label]. For oral use, afatinib tablets are a first-line (initial) treatment for patients with metastatic non-small cell lung cancer (NSCLC) with common epidermal growth factor receptor (EGFR) mutations...
Approved
Matched Iupac: … (2E)-N-{4-[(3-chloro-4-fluorophenyl)amino]-7-[(3S)-oxolan-3-yloxy]quinazolin-6-yl}-4-(dimethylamino)but …
Matched Description: … Afatinib is a 4-anilinoquinazoline tyrosine kinase inhibitor in the form of a dimaleate salt available …
Matched Salts cas: … 850140-73-7 …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Matched Description: … Afatinib is a 4-anilinoquinazoline tyrosine kinase inhibitor in the form of a dimaleate salt available …
Matched Salts cas: … 850140-73-7 …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
scAAV9.U7.ACCA
scAAV9.U7.ACCA is a non-replicating recombinant adeno-associated virus vector containing 4 antisense sequences designed to target exon 2 in the human DMD gene under the control of U7 small nuclear non-coding RNA. Developed by Nationwide Children’s Hospital, it is being investigated for the treatment of Duchenne muscular dystrophy.
Investigational
Matched Synonyms: … 2 in the human DMD gene under the control of U7 small nuclear non-coding RNA ... non-replicating recombinant adeno-associated virus vector containing 4 antisense sequences designed to target exon …
Matched Description: … 2 in the human DMD gene under the control of U7 small nuclear non-coding RNA. ... non-replicating recombinant adeno-associated virus vector containing 4 antisense sequences designed to target exon ... Developed by Nationwide Children’s Hospital, it is being investigated for the treatment of Duchenne muscular …
Matched Description: … 2 in the human DMD gene under the control of U7 small nuclear non-coding RNA. ... non-replicating recombinant adeno-associated virus vector containing 4 antisense sequences designed to target exon ... Developed by Nationwide Children’s Hospital, it is being investigated for the treatment of Duchenne muscular …
Displaying all 9 drugs